The vaccines and treatments being developed for Ebola outbreak

More than 875 cases of the Bundibugyo strain of Ebola have been confirmed, including 202 deaths, in DR Congo and Uganda. No vaccines or treatments exist for this strain, but several candidates are being developed. The WHO considers an rVSV-based vaccine the most promising, but it may take 7-9 months for human trials. Oxford and Moderna are working on vaccines that could start phase 1 trials in 2-3 months, possibly by July. CEPI is funding these efforts. For treatments, WHO recommends remdesivir, MBP134, and Maftivimab for swift trials.

More than 875 cases of the Bundibugyo strain of Ebola have been confirmed, including 202 deaths, in DR Congo and Uganda. No vaccines or treatments exist for this strain, but several candidates are being developed. The WHO considers an rVSV-based vaccine the most promising, but it may take 7-9 months for human trials. Oxford and Moderna are working on vaccines that could start phase 1 trials in 2-3 months, possibly by July. CEPI is funding these efforts. For treatments, WHO recommends remdesivir, MBP134, and Maftivimab for swift trials.

More than 875 cases of the Bundibugyo strain of Ebola have been confirmed, including 202 deaths, in DR Congo and Uganda. No vaccines or treatments exist for this strain, but several candidates are being developed. The WHO considers an rVSV-based vaccine the most promising, but it may take 7-9 months for human trials. Oxford and Moderna are working on vaccines that could start phase 1 trials in 2-3 months, possibly by July. CEPI is funding these efforts. For treatments, WHO recommends remdesivir, MBP134, and Maftivimab for swift trials.

This story involves 1 source and may affect public understanding of vaccine development / ebola outbreak.